The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on m...

Full description

Bibliographic Details
Main Authors:	Virginia Liberini, Martin W. Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E. Pellerito, Mauro G. Papotti, Alessandro Piovesan, Emanuela Arvat, Désirée Deandreis
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	Diagnostics
Subjects:	peptide receptor radionuclide therapy PRRT 68Ga-labeled somatostatin analogue 18F-FDG response assessment RECIST
Online Access:	https://www.mdpi.com/2075-4418/10/12/1083

id	doaj-d18426241e8b43d99e21184b656ee7ff
record_format	Article
spelling	doaj-d18426241e8b43d99e21184b656ee7ff2020-12-13T00:02:44ZengMDPI AGDiagnostics2075-44182020-12-01101083108310.3390/diagnostics10121083The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the FutureVirginia Liberini0Martin W. Huellner1Serena Grimaldi2Monica Finessi3Philippe Thuillier4Alfredo Muni5Riccardo E. Pellerito6Mauro G. Papotti7Alessandro Piovesan8Emanuela Arvat9Désirée Deandreis10Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, 10126 Turin, ItalyDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, SwitzerlandNuclear Medicine Unit, Department of Medical Sciences, University of Turin, 10126 Turin, ItalyNuclear Medicine Unit, Department of Medical Sciences, University of Turin, 10126 Turin, ItalyNuclear Medicine Unit, Department of Medical Sciences, University of Turin, 10126 Turin, ItalyNuclear Medicine Department, S.S. Biagio e Antonio e C. Arrigo Hospital, 15121 Alessandria, ItalyNuclear Medicine Department, AO Ordine Mauriziano di Torino, 10128 Turin, ItalyPathology Unit, City of Health and Science University Hospital, 10126 Turin, ItalyDepartment of Endocrinology, A. O. U. Città della Salute della Scienza of Turin, 10126 Turin, ItalyOncological Endocrinology, Department of Medical Sciences, University of Turin,10126 Turin, ItalyNuclear Medicine Unit, Department of Medical Sciences, University of Turin, 10126 Turin, ItalyThe NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owed to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT.https://www.mdpi.com/2075-4418/10/12/1083peptide receptor radionuclide therapyPRRT68Ga-labeled somatostatin analogue18F-FDGresponse assessmentRECIST
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Virginia Liberini Martin W. Huellner Serena Grimaldi Monica Finessi Philippe Thuillier Alfredo Muni Riccardo E. Pellerito Mauro G. Papotti Alessandro Piovesan Emanuela Arvat Désirée Deandreis
spellingShingle	Virginia Liberini Martin W. Huellner Serena Grimaldi Monica Finessi Philippe Thuillier Alfredo Muni Riccardo E. Pellerito Mauro G. Papotti Alessandro Piovesan Emanuela Arvat Désirée Deandreis The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future Diagnostics peptide receptor radionuclide therapy PRRT 68Ga-labeled somatostatin analogue 18F-FDG response assessment RECIST
author_facet	Virginia Liberini Martin W. Huellner Serena Grimaldi Monica Finessi Philippe Thuillier Alfredo Muni Riccardo E. Pellerito Mauro G. Papotti Alessandro Piovesan Emanuela Arvat Désirée Deandreis
author_sort	Virginia Liberini
title	The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
title_short	The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
title_full	The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
title_fullStr	The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
title_full_unstemmed	The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
title_sort	challenge of evaluating response to peptide receptor radionuclide therapy in gastroenteropancreatic neuroendocrine tumors: the present and the future
publisher	MDPI AG
series	Diagnostics
issn	2075-4418
publishDate	2020-12-01
description	The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owed to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT.
topic	peptide receptor radionuclide therapy PRRT 68Ga-labeled somatostatin analogue 18F-FDG response assessment RECIST
url	https://www.mdpi.com/2075-4418/10/12/1083
work_keys_str_mv	AT virginialiberini thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT martinwhuellner thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT serenagrimaldi thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT monicafinessi thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT philippethuillier thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT alfredomuni thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT riccardoepellerito thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT maurogpapotti thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT alessandropiovesan thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT emanuelaarvat thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT desireedeandreis thechallengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT virginialiberini challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT martinwhuellner challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT serenagrimaldi challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT monicafinessi challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT philippethuillier challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT alfredomuni challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT riccardoepellerito challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT maurogpapotti challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT alessandropiovesan challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT emanuelaarvat challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture AT desireedeandreis challengeofevaluatingresponsetopeptidereceptorradionuclidetherapyingastroenteropancreaticneuroendocrinetumorsthepresentandthefuture
_version_	1724385585946165248

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

Similar Items